{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:56:50Z","timestamp":1790546210362,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e36298","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T05:27:52Z","timestamp":1724390872000},"page":"e36298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting TAG-72 in cutaneous T cell lymphoma"],"prefix":"10.1016","volume":"10","author":[{"given":"Vera J.","family":"Evtimov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maree V.","family":"Hammett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleta","family":"Pupovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu-Y N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runzhe","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Van Der Weyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Twigger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian T.","family":"Nisbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan O.","family":"Trounson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e36298_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/cco.2019.01.02","article-title":"Systemic therapy of cutaneous T-cell lymphoma (CTCL)","volume":"8","author":"Alpdogan","year":"2019","journal-title":"Chin. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36298_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis fungoides and Sezary syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36298_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2008-04-153031","article-title":"Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome","volume":"113","author":"van Doorn","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36298_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1586\/edm.12.7","article-title":"Mycosis fungoides and S\u00e9zary syndrome: clinical, immunological and molecular distinctions that suggest two different diseases","volume":"7","author":"Wu","year":"2012","journal-title":"Expet Rev. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36298_bib5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/cyto.b.20395","article-title":"CD158k\/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sezary syndrome by flow cytometry","volume":"74","author":"Bahler","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e36298_bib6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in Sezary syndrome and mycosis fungoides","volume":"148","author":"Cetinozman","year":"2012","journal-title":"Arch. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36298_bib7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e36298_bib8","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1182\/bloodadvances.2022008562","article-title":"Sezary syndrome originates from heavily mutated hematopoietic progenitors","volume":"7","author":"Harro","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36298_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36298_bib10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020","volume":"18","author":"Mehta-Shah","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.heliyon.2024.e36298_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36298_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36298_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e36298_bib14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e36298_bib15","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36298_bib16","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.heliyon.2024.e36298_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fonc.2019.00259","article-title":"CAR-based approaches to cutaneous T-cell lymphoma","volume":"9","author":"Scarfo","year":"2019","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36298_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nri.2018.3","article-title":"The tumour glyco-code as a novel immune checkpoint for immunotherapy","volume":"18","author":"Rodriguez","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36298_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00004347-198709000-00005","article-title":"Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissues","volume":"6","author":"Thor","year":"1987","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36298_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/dc.20343","article-title":"Cytomorphology of gastric and duodenal epithelium and reactivity to B72.3: a baseline for comparison to pancreatic lesions aspirated by EUS-FNAB","volume":"33","author":"Nagle","year":"2005","journal-title":"Diagn. Cytopathol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36298_bib21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/ijc.2910440607","article-title":"Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer","volume":"44","author":"Xu","year":"1989","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36298_bib22","first-page":"953","article-title":"Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity","volume":"5","author":"Rosenblum","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e36298_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e36298_bib24","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective Targeting of TAG72+ peritoneal ovarian Tumors via regional Delivery of CAR-engineered T cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36298_bib25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.omto.2021.01.002","article-title":"Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer","volume":"20","author":"Shu","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"23","key":"10.1016\/j.heliyon.2024.e36298_bib26","doi-asserted-by":"crossref","first-page":"12933","DOI":"10.3390\/ijms222312933","article-title":"Malignant and benign T cells constituting cutaneous T-cell lymphoma","volume":"22","author":"Nakai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e36298_bib27","first-page":"1123","article-title":"Expression of tumor-associated glycoprotein-72 (TAG-72) antigen in human prostatic adenocarcinomas","volume":"8","author":"Karan","year":"2001","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36298_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canlet.2006.11.025","article-title":"Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis","volume":"251","author":"Ponnusamy","year":"2007","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36298_bib29","first-page":"3118","article-title":"Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3","volume":"46","author":"Thor","year":"1986","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e36298_bib30","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36298_bib31","volume":"vol. 2010","author":"Cartellieri","year":"2010"},{"key":"10.1016\/j.heliyon.2024.e36298_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.heliyon.2024.e36298_bib33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fcell.2020.00851","article-title":"Cellular interactions and inflammation in the pathogenesis of cutaneous T-cell lymphoma","volume":"8","author":"Stolearenco","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36298_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000218050","article-title":"TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines","volume":"18","author":"Nicolet","year":"1997","journal-title":"Tumour Biol"},{"key":"10.1016\/j.heliyon.2024.e36298_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36298_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/cyto.b.21888","article-title":"Sezary syndrome and mycosis fungoides: an overview, including the role of immunophenotyping","volume":"100","author":"Pulitzer","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e36298_bib37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cll.2017.06.006","article-title":"Cutaneous T-cell lymphoma","volume":"37","author":"Pulitzer","year":"2017","journal-title":"Clin. Lab. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e36298_bib38","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/archdermatol.2010.200","article-title":"Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression","volume":"146","author":"Samimi","year":"2010","journal-title":"Arch. Dermatol."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e36298_bib39","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood-2017-06-792382","article-title":"KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting","volume":"130","author":"Battistella","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e36298_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12071582","article-title":"TOX expression in mycosis fungoides and Sezary syndrome","volume":"12","author":"Pileri","year":"2022","journal-title":"Diagnostics"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e36298_bib41","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.jaad.2018.06.025","article-title":"CADM1 is a diagnostic marker in early-stage mycosis fungoides: multicenter study of 58 cases","volume":"79","author":"Yuki","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36298_bib42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.heliyon.2024.e36298_bib43","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e36298_bib44","article-title":"The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer","volume":"1876","author":"Xu","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"F1000 Faculty Rev","key":"10.1016\/j.heliyon.2024.e36298_bib45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.12688\/f1000research.21922.1","article-title":"Recent advances in understanding and managing cutaneous T-cell lymphomas","volume":"9","author":"Brunner","year":"2020","journal-title":"F1000Res"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024123298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024123298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:08:56Z","timestamp":1790543336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024123298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":45,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024123298"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36298","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting TAG-72 in cutaneous T cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e36298"}}